Viridian Therapeutics price target raised to $61 from $56 at BTIG

BTIG raised the firm’s price target on Viridian Therapeutics (VRDN) to $61 from $56 and keeps a Buy rating on the shares. A key unknown for the company was whether the subcutaneous – SC – Phase 3 trial of Tepezza initiated by Amgen (AMGN) earlier this year is studying an autoinjector or on body device, and while Amgen has been guarded on the detail, a recent site-specific entry publicly confirms that the SC formulation of Tepezza in the ongoing Phase 3 trial is a Q2W on body device, the analyst tells investors in a research note. This is likely leaving VRDN-003 in the pole position as the best-in-category SC Tx option for TED, the firm added.